POD Technology

Impel NeuroPharma’s POD™ nasal drug delivery platform is designed to deliver drugs to the upper nasal cavity for improved biodistribution. By delivering therapeutics to the upper nasal cavity, the POD™ nasal delivery platform takes advantage of the vascular rich olfactory region for improved bioavailability and has the potential to directly target the brain via the olfactory and trigeminal nerves. Delivery of therapeutically meaningful levels of drugs may allow for the development of more effective formulations of existing drugs, as well as the development of novel drugs that otherwise would not cross the blood-brain barrier, thereby expanding the range of treatment options available to patients.

The nasal cavity is a vastly underutilized entry point for therapeutics into systemic circulation. The primary challenge in achieving significant nasal drug delivery is depositing drugs in the deeper regions of the nasal cavity where systemic absorption may be more consistent. Due to the complex architecture of this area, drugs delivered with standard nasal devices such as droppers, sprays, or pumps typically deposit less than 5% of the compound into the olfactory region and thus, do not contribute meaningfully to systemic levels. In addition, these low levels do not provide a significant opportunity to treat CNS disorders. Impel’s POD™ technology results in a large fraction of drug deposition in this region, which can lead to direct uptake along the olfactory pathways, as well as greater and faster uptake into the systemic vasculature (depending on the drug).


• Consistency
• Accuracy
• Unit dose or multidose
• Liquid and dry powder compatible
• No breath coordination required
• Low cost, Disposable


• Rapid for fast acting relief
• Efficient due to targeted delivery
• Non-invasive for chronic conditions
• Hand-held, easy to use for all populations
• Self or caregiver administered
• ER use for unconscious patients


• Formulation development
• Drug-device compatibility
• Translational studies
• Clinical testing
• Regulatory clearance
• Manufacturing

Selected Studies

To learn more about our innovative technology, we recommend reading the following:


Hoekman JD and Ho RJY. Enhanced Analgesic Responses Following Preferential Delivery of Morphine and Fentanyl to the Olfactory Epithelium. Anesthesia and Analgesia. Sept 2011 Volume 113(3): 641-51. PubMed: 21709146

Landis MS, Boyden T, Pegg S. Nasal-to-CNS drug delivery: where are we now and where are we heading? An industrial perspective. Ther Deliv. Feb 2012;3(2):195-208. Review. PubMed: 22834197

Lochhead JJ, Thorne RG. Intranasal Delivery of Biologics to the Central Nervous System. Adv Drug Deliv Rev. 2011 Nov 15. PubMed: 22119441



J. Hoekman, A. Brunelle, M. Hite, P. Kim, C. Fuller. Impel NeuroPharma, Inc. Usability and Tolerability Study in Human Subjects with a Novel Precision Olfactory Delivery (POD) Device. Presented at AAPS 2013. PDF

J. Hoekman, A. Brunelle, M. Hite, P. Kim, C. Fuller. Impel NeuroPharma, Inc. SPECT Imaging of Direct Nose-to-Brain Transfer of MAG-3 in Man. Presented at AAPS 2013. PDF


Impel NeuroPharma, Inc. is active in the areas of biomedical research and drug delivery systems.

This page is intended to serve as notice under 35 U.S.C. § 287(a).


U.S. Pat. No. 9,550,036. Other patents pending.